REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.89
+1.16%Next report
Analyst consensus
- Next report date
- Feb 2, 2027
- EPS estimate
- -$0.57
- Revenue estimate
- $10.8M
Latest reported
- Last report date
- Oct 28, 2026
- EPS actual
- -$0.54
- EPS estimate
- -$0.78
- Revenue actual
- —
- Revenue estimate
- $1.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +5.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $24
- PT range
- $19 – $31
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 28, 2026 | -$0.78 | -$0.54 | Beat 31.12% | — |
| Aug 14, 2026 | -$0.69 | -$0.72 | Miss -3.75% | — |
| Jun 29, 2026 | -$0.66 | -$0.76 | Miss -14.93% | — |
| Feb 3, 2026 | -$0.85 | -$0.77 | Beat 9.41% | — |
| Nov 6, 2025 | -$0.87 | -$0.90 | Miss -3.45% | — |
| Aug 7, 2025 | -$0.83 | -$0.95 | Miss -14.46% | — |
| May 22, 2025 | -$0.75 | -$0.82 | Miss -9.33% | $1.5M |
| Feb 12, 2025 | -$0.70 | -$0.79 | Miss -12.86% | — |
| Aug 8, 2024 | -$0.88 | -$0.78 | Beat 11.36% | — |
| May 16, 2024 | -$0.86 | -$0.82 | Beat 4.65% | $4.0M |
| Feb 8, 2024 | -$0.94 | -$0.77 | Beat 18.09% | — |
| Aug 3, 2023 | -$0.85 | -$0.75 | Beat 11.76% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 2, 2027